MNKD
HEALTHCAREMannKind Corp
AI Insight
What's Moving MNKD Today?
No stock-specific AI insight has been generated for MNKD yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring MNKD
52-Week Range
$2.23$6.51
$3.91
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-6.6%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding309.0M
MNKD News
24 articles- MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DYahoo Finance·Jun 23, 2026
- Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”Yahoo Finance·Jun 13, 2026
- 7 Hidden Penny Stocks to Invest InInsider Monkey·Jun 12, 2026
- MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical DataYahoo Finance·Jun 12, 2026
- Jim Cramer Says He Blessed MannKind as a Speculation OnlyYahoo Finance·Jun 8, 2026
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsGlobeNewswire Inc.·Jun 5, 2026
- MannKind (MNKD) Advances Clinical Trials for Inhaled IPF TherapyYahoo Finance·Jun 5, 2026
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFYahoo Finance·Jun 3, 2026
- MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed?Yahoo Finance·Jun 1, 2026
- MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes MarketMarketbeat·May 31, 2026
- FDA approves Afrezza for children and adolescents with diabetesManaged Healthcare Executive·May 29, 2026
- MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In ChildrenStocktwits·May 29, 2026
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalGlobeNewswire Inc.·May 29, 2026
- MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesYahoo Finance·May 29, 2026
- MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes TreatmentStocktwits·May 28, 2026
- MannKind to Present at Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) SystemsYahoo Finance·May 27, 2026
- MannKind Corporation 8-K Filing Details Board Election Results and Company Information (May 2026)Minichart·May 23, 2026
- MannKind (NASDAQ: MNKD) reports 2026 annual meeting voting resultsStock Titan·May 22, 2026
- MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2MYahoo Finance·May 18, 2026
- ARKO Petroleum And 2 Other Value Stocks Priced Below Estimated WorthYahoo Finance·May 13, 2026
- Wells Fargo Raises its Price Target on MannKind (MNKD) to $10Yahoo Finance·May 13, 2026
- H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price TargetsYahoo Finance·May 11, 2026
- MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's ChangedYahoo Finance·May 8, 2026
All 24 articles loaded
Price Data
Open$3.86
Previous Close$3.89
Day High$3.94
Day Low$3.85
52 Week High$6.51
52 Week Low$2.23
52-Week Range
$2.23$6.51
$3.91
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-6.6%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding309.0M
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—